Eton Pharmaceuticals Stock Forecast, Price & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eton Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Eton Pharmaceuticals stock.
View analyst ratings for Eton Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Eton Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Eton Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Eton Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 11th 2021.
View our earnings forecast for Eton Pharmaceuticals.

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) posted its quarterly earnings results on Thursday, May, 13th. The company reported $0.19 EPS for the quarter, meeting the consensus estimate of $0.19.
View Eton Pharmaceuticals' earnings history.

Eton Pharmaceuticals' stock was trading at $4.20 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ETON stock has increased by 42.4% and is now trading at $5.98.
View which stocks have been most impacted by COVID-19.

2 brokerages have issued twelve-month price objectives for Eton Pharmaceuticals' shares. Their forecasts range from $11.00 to $14.00. On average, they anticipate Eton Pharmaceuticals' stock price to reach $12.50 in the next year. This suggests a possible upside of 109.0% from the stock's current price.
View analysts' price targets for Eton Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Some companies that are related to Eton Pharmaceuticals include Applied Therapeutics (APLT), Geron (GERN), ZIOPHARM Oncology (ZIOP), Bolt Biotherapeutics (BOLT), AC Immune (ACIU), Eagle Pharmaceuticals (EGRX), Inventiva (IVA), Mirum Pharmaceuticals (MIRM), BELLUS Health (BLUSF), Selecta Biosciences (SELB), Provention Bio (PRVB), IVERIC bio (ISEE), Forte Biosciences (FBRX), Magenta Therapeutics (MGTA) and Relmada Therapeutics (RLMD).
View all of ETON's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Eton Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Amarin (AMRN), Myovant Sciences (MYOV), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), Vaxart (VXRT), CymaBay Therapeutics (CBAY), Fulcrum Therapeutics (FULC) and Moderna (MRNA).

(ETON) raised $22 million in an IPO on Wednesday, November 14th 2018. The company issued 3,600,000 shares at $6.00 per share. National Securities Corporation served as the underwriter for the IPO.

Eton Pharmaceuticals trades on the NASDAQ under the ticker symbol "ETON."

Eton Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (4.44%), AWM Investment Company Inc. (3.67%), Geode Capital Management LLC (1.08%), Northern Trust Corp (0.73%), Westside Investment Management Inc. (0.35%) and Sei Investments Co. (0.30%). Company insiders that own Eton Pharmaceuticals stock include Charles J Casamento, Harrow Health, Inc, Opaleye Management Inc and Sean Brynjelsen.
View institutional ownership trends for Eton Pharmaceuticals.

ETON stock was sold by a variety of institutional investors in the last quarter, including MML Investors Services LLC, AWM Investment Company Inc., JPMorgan Chase & Co., Northern Trust Corp, Sei Investments Co., Diametric Capital LP, and Nuveen Asset Management LLC. Company insiders that have sold Eton Pharmaceuticals company stock in the last year include Harrow Health, Inc, and Opaleye Management Inc.
View insider buying and selling activity for Eton Pharmaceuticals or view top insider-selling stocks.

ETON stock was acquired by a variety of institutional investors in the last quarter, including Geode Capital Management LLC, GSA Capital Partners LLP, BlackRock Inc., Barclays PLC, and Westside Investment Management Inc.. Company insiders that have bought Eton Pharmaceuticals stock in the last two years include Charles J Casamento, Opaleye Management Inc, and Sean Brynjelsen.
View insider buying and selling activity for Eton Pharmaceuticals or or view top insider-buying stocks.

Shares of ETON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ETON stock can currently be purchased for approximately $5.98.

Eton Pharmaceuticals has a market capitalization of $146.56 million and generates $40,000.00 in revenue each year. The company earns $-27,970,000.00 in net income (profit) each year or ($1.33) on an earnings per share basis.

Eton Pharmaceuticals employs 16 workers across the globe.

The official website for Eton Pharmaceuticals is www.etonpharma.com.

Eton Pharmaceuticals is headquartered at 21925 W. FIELD PARKWAY SUITE 235, DEER PARK IL, 60010.

Eton Pharmaceuticals' mailing address is 21925 W. FIELD PARKWAY SUITE 235, DEER PARK IL, 60010. The company can be reached via phone at 847-787-7361 or via email at [email protected]